Seeking Alpha - 2 天前查看原文
Enliven Therapeutics: Still Too Early To Pay This Much
Enliven's initial phase 1 data for ELVN-001 in CML shows promising tolerability and activity in heavily pretreated patients. But read why ELVN stock is a Sell.
快來搶先討論吧!
快來聊聊你的看法
快來搶先討論吧!
快來聊聊你的看法